More about McKesson Corporation
Regulatory Filings for McKesson Corporation
Fundamentals for McKesson Corporation
Fraud, Delays, and High Fees—Gone: The Underrated Fintech Shift Reshaping U.S. Local Economies
From Rhode Island to Vermont: The Proficiency Gap That's Quietly Dividing New England's Workforce
Regional Airports Poised for Growth Amid Airline Shakeups
From Fuel Shock to Factory Revival: The Surprising Rise of Hyper-Local Supply Chains in the U.S.
Fundamentals for McKesson Corporation
Business Operations:
Sector: HealthcareIndustry: Medical Distribution
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners to address challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver solutions to help people get the medicine needed to live healthier lives; and provides medication access and affordability, prescription decision support, prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services, as well as electronic prior authorization services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, biomedical maintenance, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health care agencies. The International segment delivers medicines, supplies, and information technology solutions to retail pharmacies, hospitals, long-term care centers, clinics and institutions; and provides logistics and distribution services for manufacturers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Revenue projections:
MCK's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.
Financial Ratios:
| currentRatio | 0.87600 |
|---|---|
| forwardPE | 18.84705 |
| debtToEquity | 0.00000 |
| earningsGrowth | 0.38000 |
| revenueGrowth | 0.11400 |
| grossMargins | 0.03453 |
| operatingMargins | 0.01545 |
| trailingEps | 34.66000 |
| forwardEps | 44.10823 |
MCK's Forward PE ratio is in a good range, reflecting a reasonable balance between stock price and earnings. The stock is not overpriced, leaving room for growth, which suggests potential for investors looking to capitalize on future value appreciation.
MCK's positive earnings and revenue growth indicate that the company is well-positioned for business expansion. This growth suggests a strong financial trajectory, with MCK expected to continue increasing its profits and revenue in the coming periods.
McKesson Corporation's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in McKesson Corporation's earnings potential, suggesting stronger financial performance compared to the previous year.
Price projections:
Over time, price projections for MCK have gradually risen, signaling growing optimism about the company's future. This upward revision reflects increasing confidence in MCK's ability to achieve strong financial results.
Insider Transactions:
MCK saw 24 transactions in which shares were sold with market price at 746.1450068155924.The period under consideration saw no sell transactions.An increase in buying activity relative to selling at MCK's current price might suggest a favorable sentiment among investors. This trend could be interpreted as a sign that the stock has a positive outlook in the near term.
Recommendation changes over time:
MCK has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view MCK as a reliable choice for their money, offering a promising avenue for future growth and financial gains.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst technicals.
Latest Regulatory Filings for SP5
Companies with the best and the worst fundamentals.
AI Data Centers Transform Small-Town USA: Jobs, Taxes, and Tech Ecosystems Explode
The $919 Billion Warning: What the Wholesale Inventory Explosion Really Means for Main Street
How U.S. Cities Are Turning Data and Infrastructure into Billion-Dollar Opportunities